These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 9924703)
1. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer. Rucker R; Bresler HS; Heffelfinger M; Kim JA; Martin EW; Triozzi PL J Immunother; 1999 Jan; 22(1):80-4. PubMed ID: 9924703 [TBL] [Abstract][Full Text] [Related]
2. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551 [TBL] [Abstract][Full Text] [Related]
3. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity. Liljefors M; Nilsson B; Mellstedt H; Frödin JE Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322 [TBL] [Abstract][Full Text] [Related]
4. Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Ragnhammar P; Fagerberg J; Frödin JE; Wersäll P; Hansson LO; Mellstedt H Cancer Immunol Immunother; 1995 Jun; 40(6):367-75. PubMed ID: 7627993 [TBL] [Abstract][Full Text] [Related]
5. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. Fukuda M; Horibe K; Furukawa K Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237 [TBL] [Abstract][Full Text] [Related]
7. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873 [TBL] [Abstract][Full Text] [Related]
8. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced. Ragnhammar P; Fagerberg J; Frödin JE; Hjelm AL; Lindemalm C; Magnusson I; Masucci G; Mellstedt H Int J Cancer; 1993 Mar; 53(5):751-8. PubMed ID: 8449598 [TBL] [Abstract][Full Text] [Related]
9. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Ragnhammar P; Friesen HJ; Frödin JE; Lefvert AK; Hassan M; Osterborg A; Mellstedt H Blood; 1994 Dec; 84(12):4078-87. PubMed ID: 7994026 [TBL] [Abstract][Full Text] [Related]
10. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Fagerberg J; Frödin JE; Ragnhammar P; Steinitz M; Wigzell H; Mellstedt H Cancer Immunol Immunother; 1994 Mar; 38(3):149-59. PubMed ID: 8124683 [TBL] [Abstract][Full Text] [Related]
11. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor. Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H Clin Cancer Res; 1998 Aug; 4(8):1921-9. PubMed ID: 9717820 [TBL] [Abstract][Full Text] [Related]
12. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE Int J Oncol; 2004 Sep; 25(3):703-11. PubMed ID: 15289873 [TBL] [Abstract][Full Text] [Related]
13. A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. Posey JA; Raspet R; Verma U; Deo YM; Keller T; Marshall JL; Hodgson J; Mazumder A; Hawkins MJ J Immunother; 1999 Jul; 22(4):371-9. PubMed ID: 10404439 [TBL] [Abstract][Full Text] [Related]
14. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. Murray JL; Kleinerman ES; Jia SF; Rosenblum MG; Eton O; Buzaid A; Legha S; Ross MI; Thompson L; Mujoo K; Rieger PT; Saleh M; Khazaeli MB; Vadhan-Raj S J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):206-17. PubMed ID: 8811495 [TBL] [Abstract][Full Text] [Related]
15. The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC). Ragnhammar P; Magnusson I; Masucci G; Mellstedt H Med Oncol Tumor Pharmacother; 1993; 10(1-2):61-70. PubMed ID: 8258997 [TBL] [Abstract][Full Text] [Related]
16. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor. Ragnhammar P; Masucci G; Frödin JE; Hjelm AL; Mellstedt H Cancer Immunol Immunother; 1992; 35(3):158-64. PubMed ID: 1638551 [TBL] [Abstract][Full Text] [Related]
17. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Estey EH; Kurzrock R; Talpaz M; McCredie KB; O'Brien S; Kantarjian HM; Keating MJ; Deisseroth AB; Gutterman JU Br J Haematol; 1991 Mar; 77(3):291-5. PubMed ID: 2012752 [TBL] [Abstract][Full Text] [Related]
18. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469 [TBL] [Abstract][Full Text] [Related]
19. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project. Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393 [TBL] [Abstract][Full Text] [Related]
20. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Neidhart J; Allen KO; Barlow DL; Carpenter M; Shaw DR; Triozzi PL; Conry RM Vaccine; 2004 Jan; 22(5-6):773-80. PubMed ID: 14741172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]